The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: A prospective, placebo-controlled randomized trial (EVAPORATE): Interim Results
Association of HDL subclasses with baseline coronary plaque burden by coronary computed tomography angiography (CCTA) from EVAPORATE (effect of Vascepa on improving coronary atherosclerosis in people with high triglycerides taking statin therapy) trial [abstract].
Risk of cardiovascular events in patients with hypertriglyceridemia: a review of real-world evidence.
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
Eicosapentaenoic acid (EPA) inhibits human low-density lipoprotein oxidation in a concentration- and time-dependent manner at pharmacologic doses in vitro [abstract EAS19-0568].
Eicosapentaenoic acid, but not a mixed omega-3 fatty acid supplement, improved nitric oxide bioavailability in human endothelial cells in vitro.
Eicosapentaenoic acid (EPA) containing phospholipids modulate membrane structure.